|
|
Vaccine Detail
|
Melanoma DNA vaccine xenogeneic DNA encoding murine tyrosinase |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004465
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Dog
- Tyrosinase from Mouse
gene engineering:
- Type: DNA vaccine construction
- Description: Vector pING expressed murine tyrosinase (Manley et al., 2011).
- Detailed Gene Information: Click Here.
- Vector: pING plasmid vector (Manley et al., 2011)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Dog Response
- Vaccine Immune Response Type: VO_0000286
- Efficacy: Overall median survival time (MST) for dogs treated with loco-regional control and xenogeneic DNA vaccine was 476 days with a 1-year survival rate of 63%. The xenogeneic murine tyrosinase DNA vaccine was safe and appears effective when used in conjunction with local and regional disease control (Manley et al., 2011).
|
| References |
Manley et al., 2011: Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2011; 25(1); 94-99. [PubMed: 21143299].
|
|
